Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!

 
As part of Myeloma Patients Europe’s (MPE) ongoing work to ensure that the patient voice is fully represented, and to strengthen organizations’ and individuals’ ability to advocate effectively, in 2017 MPE created the Advocate Development Program (ADP). The ADP is a 12-month training programme designed to develop participants’ advocacy knowledge and skills to better serve patients locally, nationally, and across Europe. Through the course, participants improve their understanding of clinical research and development, mechanisms of accessing diagnostics and drugs, interaction with stakeholders including clinicians and industry, and the basics of evidence-based advocacy.

Ananda Plate, CEO of Myeloma Patients Europe, explains in this video the main objectives of this programme:
 
 
The ADP combines virtual and in-person lectures to educate advocates on the disease and treatment of myeloma and AL amyloidosis as well as the entire drug development process. Participants will learn from experts in their fields to understand the research, development, and regulatory processes and how advocates can influence and shape these to improve patient experiences and outcomes. In addition to monthly sessions, the programme includes participation in important myeloma scientific meetings in Europe (attendance sponsored by MPE) such as the European Haematology Association (EHA) Annual Meeting and the European Cancer (ECCO) Summit.
 

Who should apply for the ADP?

Patients, carers, advocates, and community members who are interested in developing professional advocacy skills in the fields of myeloma and AL amyloidosis and who are committed to improving outcomes for patients across Europe.
 

Applicants for the ADP 2021 must meet all the following requirements:
  • Commitment to attend 13 virtual lectures, 1 – 2 hours each
  • Commitment to invest an additional 40 learning and homework hours (e.g. pre-reads, case studies, responding to questions, and completing assessments and evaluations).
  • Commitment to attend the full duration of the following congresses (with travel and accommodation covered by MPE):
    • EHA Annual Congress (10 – 13 June 2021, Vienna)
    • ECCO European Cancer Summit (November 2021, exact date and location TBD)
    • MPE AGM 2022 (If sponsored based on course attendance; exact date and location TBD).
  • Fluency in English is essential to participate in lectures and discussions
  • Participants are required to have access to a working computer with a functioning camera and audio
  • The ADP welcomes patient advocates with any kind of professional background. However, healthcare professionals who are actively practicing their medical profession (e.g. as a haematologist or nurse in a clinic) are not eligible to apply for this programme.

Where this is required, MPE can provide accommodations for participants in the Advocate Development Programme. We would be happy to speak with you about this during the enrolment process.

If you are interested in joining the MPE Advocate Development Programme in 2021, please fill in the form below before October 31, 2020.
Please, reach out to Katie Joyner, the MPE Patient Advocacy Programme Manager, at joyner@mpeurope.org with any questions.
 

  • This form collects the data shown below so we can evaluate your MPE ADP 2020 application. Check out our privacy policy to see how we protect and manage your submitted data.
  • Please describe your experience and skills in relation to patient advocacy and in the interaction with stakeholders (clinicians, regulators, industry, etc.)
  • Please describe your motivation, goals, objectives and expectations from participating in the MPE ADP. We would like to see how your participation in this training can contribute to myeloma/AL-amyloidosis advocacy in your country, region or in Europe. In addition, please mention what will be your unique contribution to the training and to your patient community. You may want to highlight how your professional and/or educational experience fit with the ADP objectives. Please ensure that your motivation letter is no longer than 1000 words.